Association of Urine Metanephrine Levels with CardiometaBolic Risk: An Observational Retrospective Study
No research has explored the role of catecholamine metabolites in the stratification of cardiovascular risk. We aimed to evaluate the relationship between urine metanephrines and cardiometabolic risk/complications. In this retrospective cross-sectional study, we collected the data of 1374 patients s...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/9/1967 |
| _version_ | 1797535272735342592 |
|---|---|
| author | Mirko Parasiliti-Caprino Chiara Obert Chiara Lopez Martina Bollati Fabio Bioletto Chiara Bima Filippo Egalini Alessandro Maria Berton Nunzia Prencipe Fabio Settanni Valentina Gasco Giulio Mengozzi Ezio Ghigo Mauro Maccario |
| author_facet | Mirko Parasiliti-Caprino Chiara Obert Chiara Lopez Martina Bollati Fabio Bioletto Chiara Bima Filippo Egalini Alessandro Maria Berton Nunzia Prencipe Fabio Settanni Valentina Gasco Giulio Mengozzi Ezio Ghigo Mauro Maccario |
| author_sort | Mirko Parasiliti-Caprino |
| collection | DOAJ |
| description | No research has explored the role of catecholamine metabolites in the stratification of cardiovascular risk. We aimed to evaluate the relationship between urine metanephrines and cardiometabolic risk/complications. In this retrospective cross-sectional study, we collected the data of 1374 patients submitted to the evaluation of urine metanephrines at the City of Health and Science University Hospital of Turin between 2007 and 2015, mainly for investigating the suspicion of secondary hypertension or the secretion of an adrenal lesion. The univariate analysis showed associations between metanephrines and cardiometabolic variables/parameters, particularly considering noradrenaline metabolite. At univariate regression, normetanephrine was associated with hypertensive cardiomyopathy (OR = 1.18, 95% CI 1.11–1.25; <i>p</i> < 0.001) and metabolic syndrome (OR = 1.11, 95% CI 1.03–1.20; <i>p</i> = 0.004), while metanephrine was associated with hypertensive cardiomyopathy (OR = 1.23, 95% CI 1.06–1.43; <i>p</i> = 0.006) and microalbuminuria (OR = 1.30, 95% CI 1.03–1.60; <i>p</i> = 0.018). At multivariate regression, considering all major cardiovascular risk factors as possible confounders, normetanephrine retained a significant association with hypertensive cardiomyopathy (OR = 1.14, 95% CI 1.07–1.22; <i>p</i> < 0.001) and metabolic syndrome (OR = 1.10, 95% CI 1.02–1.19; <i>p</i> = 0.017). Moreover, metanephrine retained a significant association with the presence of hypertensive cardiomyopathy (OR = 1.18, 95% CI 1.01–1.41; <i>p</i> = 0.049) and microalbuminuria (OR = 1.34, 95% CI 1.03–1.69; <i>p</i> = 0.019). The study showed a strong relationship between metanephrines and cardiovascular complications/metabolic alterations. Individuals with high levels of these indirect markers of sympathetic activity should be carefully monitored, and they may benefit from an aggressive treatment to reduce the cardiometabolic risk. |
| first_indexed | 2024-03-10T11:43:08Z |
| format | Article |
| id | doaj.art-2d2eb2a53eaa4a5594c00173c4fa073d |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T11:43:08Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-2d2eb2a53eaa4a5594c00173c4fa073d2023-11-21T18:18:32ZengMDPI AGJournal of Clinical Medicine2077-03832021-05-01109196710.3390/jcm10091967Association of Urine Metanephrine Levels with CardiometaBolic Risk: An Observational Retrospective StudyMirko Parasiliti-Caprino0Chiara Obert1Chiara Lopez2Martina Bollati3Fabio Bioletto4Chiara Bima5Filippo Egalini6Alessandro Maria Berton7Nunzia Prencipe8Fabio Settanni9Valentina Gasco10Giulio Mengozzi11Ezio Ghigo12Mauro Maccario13Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyClinical Biochemistry Laboratory, City of Health and Science University Hospital, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyClinical Biochemistry Laboratory, City of Health and Science University Hospital, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyEndocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, 10126 Turin, ItalyNo research has explored the role of catecholamine metabolites in the stratification of cardiovascular risk. We aimed to evaluate the relationship between urine metanephrines and cardiometabolic risk/complications. In this retrospective cross-sectional study, we collected the data of 1374 patients submitted to the evaluation of urine metanephrines at the City of Health and Science University Hospital of Turin between 2007 and 2015, mainly for investigating the suspicion of secondary hypertension or the secretion of an adrenal lesion. The univariate analysis showed associations between metanephrines and cardiometabolic variables/parameters, particularly considering noradrenaline metabolite. At univariate regression, normetanephrine was associated with hypertensive cardiomyopathy (OR = 1.18, 95% CI 1.11–1.25; <i>p</i> < 0.001) and metabolic syndrome (OR = 1.11, 95% CI 1.03–1.20; <i>p</i> = 0.004), while metanephrine was associated with hypertensive cardiomyopathy (OR = 1.23, 95% CI 1.06–1.43; <i>p</i> = 0.006) and microalbuminuria (OR = 1.30, 95% CI 1.03–1.60; <i>p</i> = 0.018). At multivariate regression, considering all major cardiovascular risk factors as possible confounders, normetanephrine retained a significant association with hypertensive cardiomyopathy (OR = 1.14, 95% CI 1.07–1.22; <i>p</i> < 0.001) and metabolic syndrome (OR = 1.10, 95% CI 1.02–1.19; <i>p</i> = 0.017). Moreover, metanephrine retained a significant association with the presence of hypertensive cardiomyopathy (OR = 1.18, 95% CI 1.01–1.41; <i>p</i> = 0.049) and microalbuminuria (OR = 1.34, 95% CI 1.03–1.69; <i>p</i> = 0.019). The study showed a strong relationship between metanephrines and cardiovascular complications/metabolic alterations. Individuals with high levels of these indirect markers of sympathetic activity should be carefully monitored, and they may benefit from an aggressive treatment to reduce the cardiometabolic risk.https://www.mdpi.com/2077-0383/10/9/1967catecholamineadrenalinenoradrenalineadrenergic regulationcardiovascular systemcardiovascular risk |
| spellingShingle | Mirko Parasiliti-Caprino Chiara Obert Chiara Lopez Martina Bollati Fabio Bioletto Chiara Bima Filippo Egalini Alessandro Maria Berton Nunzia Prencipe Fabio Settanni Valentina Gasco Giulio Mengozzi Ezio Ghigo Mauro Maccario Association of Urine Metanephrine Levels with CardiometaBolic Risk: An Observational Retrospective Study Journal of Clinical Medicine catecholamine adrenaline noradrenaline adrenergic regulation cardiovascular system cardiovascular risk |
| title | Association of Urine Metanephrine Levels with CardiometaBolic Risk: An Observational Retrospective Study |
| title_full | Association of Urine Metanephrine Levels with CardiometaBolic Risk: An Observational Retrospective Study |
| title_fullStr | Association of Urine Metanephrine Levels with CardiometaBolic Risk: An Observational Retrospective Study |
| title_full_unstemmed | Association of Urine Metanephrine Levels with CardiometaBolic Risk: An Observational Retrospective Study |
| title_short | Association of Urine Metanephrine Levels with CardiometaBolic Risk: An Observational Retrospective Study |
| title_sort | association of urine metanephrine levels with cardiometabolic risk an observational retrospective study |
| topic | catecholamine adrenaline noradrenaline adrenergic regulation cardiovascular system cardiovascular risk |
| url | https://www.mdpi.com/2077-0383/10/9/1967 |
| work_keys_str_mv | AT mirkoparasiliticaprino associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT chiaraobert associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT chiaralopez associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT martinabollati associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT fabiobioletto associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT chiarabima associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT filippoegalini associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT alessandromariaberton associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT nunziaprencipe associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT fabiosettanni associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT valentinagasco associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT giuliomengozzi associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT ezioghigo associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy AT mauromaccario associationofurinemetanephrinelevelswithcardiometabolicriskanobservationalretrospectivestudy |